Published in Curr Opin Oncol on March 01, 2012
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med (2016) 3.46
Integrative genomics identifies gene signature associated with melanoma ulceration. PLoS One (2013) 0.95
Inherited variation in the PARP1 gene and survival from melanoma. Int J Cancer (2014) 0.85
Modifying effect of gender on the prognostic value of clinicopathological factors and Ki67 expression in melanoma: a population-based cohort study. Biol Sex Differ (2012) 0.83
The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell Melanoma Res (2014) 0.83
Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis. Melanoma Res (2013) 0.80
Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma. J Dermatol (2016) 0.75
Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunol Immunother (2015) 0.75
Vitamin D, vitamin A, the primary melanoma transcriptome and survival. Br J Dermatol (2016) 0.75
Clinical and prognostic factors in 98 patients with malignant melanoma in China. J Int Med Res (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins. J Virol (2003) 2.31
miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res (2010) 2.24
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Involvement of p38alpha in the mitotic progression of p53(-/-) tetraploid cells. Cell Cycle (2010) 2.08
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol (2007) 2.00
FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J Immunol (2008) 1.97
Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One (2012) 1.93
RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol (2011) 1.92
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
New drugs in melanoma: it's a whole new world. Eur J Cancer (2011) 1.88
The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes. Blood (2006) 1.81
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant (2008) 1.76
Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst (2012) 1.72
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol (2013) 1.71
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol (2009) 1.68
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res (2009) 1.64
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology (2009) 1.63
Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev (2011) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol (2008) 1.49
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 1.42
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res (2007) 1.35
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (2011) 1.28
Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet (2007) 1.27
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res (2007) 1.26
Network enrichment analysis: extension of gene-set enrichment analysis to gene networks. BMC Bioinformatics (2012) 1.24
Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS One (2007) 1.23
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res (2008) 1.21
Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood (2006) 1.21
Epigenetic regulation of an IAP retrotransposon in the aging mouse: progressive demethylation and de-silencing of the element by its repetitive induction. Nucleic Acids Res (2002) 1.19
ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res (2008) 1.15
NF-kappaB and p53 are the dominant apoptosis-inducing transcription factors elicited by the HIV-1 envelope. J Exp Med (2004) 1.13
Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol (2005) 1.09
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res (2011) 1.08
Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist (2009) 1.08
Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle (2012) 1.07
Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res (2004) 1.07
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells. Clin Cancer Res (2004) 1.05
Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. Virchows Arch (2012) 1.05
Simultaneous miRNA and mRNA transcriptome profiling of human myoblasts reveals a novel set of myogenic differentiation-associated miRNAs and their target genes. BMC Genomics (2013) 1.04
Infantile convulsions with paroxysmal dyskinesia (ICCA syndrome) and copy number variation at human chromosome 16p11. PLoS One (2010) 1.04
High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS One (2009) 1.03
Kidney injuries related to ipilimumab. Invest New Drugs (2014) 1.03
Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol (2013) 1.02
Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol (2011) 1.02
MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol (2008) 1.01
Astrocytes reverted to a neural progenitor-like state with transforming growth factor alpha are sensitized to cancerous transformation. Stem Cells (2009) 1.01
Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics (2007) 1.01
Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol (2008) 1.00
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res (2007) 0.99
Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res (2013) 0.98
Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. Blood (2002) 0.98
Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages. BJU Int (2013) 0.97
Anti-CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol (2010) 0.97
FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. Cancer Res (2011) 0.96
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother (2008) 0.96
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther (2013) 0.96
Implications of personalized medicine--perspective from a cancer center. Nat Rev Clin Oncol (2011) 0.96
Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother (2008) 0.96
Vemurafenib and radiosensitization. JAMA Dermatol (2013) 0.95